Pfizer : Oncology Triad Presentation

Oncology

1

Forward-Looking Statements and Other Notices

Our discussions during Pfizer's Investor Day include forward-looking statements about our anticipated future operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read- outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits; manufacturing and product supply; our efforts to respond to COVID-19, including our investigational vaccine candidate against SARS-CoV-2 and our investigational protease inhibitor, and our expectations regarding the impact of COVID-19; our ability to successfully capitalize on growth opportunities and prospects; plans for and prospects of our acquisitions and other business development activities, including our proposed transaction with Mylan N.V. (Mylan) to combine Upjohn and Mylan to create a new global pharmaceutical company; plans relating to share repurchases and dividends; and other statements about our business, operations and financial results that are each subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Among other things, statements regarding revenue and earnings per share growth; the development or commercial potential of our product pipeline, in-line products, product candidates and additional indications, including expected clinical trial protocols, the timing of the initiation and progress of clinical trials and data read-outs from trials; the timing for the submission of applications for and receipt of regulatory approvals; expected breakthrough, best or first-in-class status, blockbuster status of our medicines or vaccines; and the impact of anticipated improvements to our clinical operation performance are forward-looking and are estimates that are subject to change and clinical trial and regulatory success. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from past results, future plans and projected future results. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com. Potential risks and uncertainties also include the impact of COVID-19 on our sales and operations, including impacts on employees, manufacturing, supply chain, marketing, research and development and clinical trials. The forward-looking statements in these presentations speak only as of the original date of the presentation and we undertake no obligation to update or revise any of these statements. Today's discussions and presentations are intended for the investor community only; they are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. All trademarks in today's presentations are the property of their respective owners.

Oncology Leadership Team

Andy Schmeltz	Chris Boshoff	Jeff Settleman	Nick Saccomano
Global President,	Chief Development Officer,	Chief Scientific Officer,	Chief Scientific Officer,
Oncology	Oncology	Oncology	Boulder R&D Unit
New York, NY	New York, NY	La Jolla, CA	Boulder, CO

3

Oncology Expected to Continue to Drive Growth for Pfizer Across a Broad Portfolio

approved cancer		32%	5-year			of revenues over
23 medicines & biosimilars		revenue CAGR		$9.9bn past 4 quarters
Breast Cancer				Genitourinary Cancers			Colorectal Cancer/Melanoma
			(1)	(2)
								(3)	(3)

Blood Cancer		Lung Cancer		Cancer Biosimilars

1. Xtandi® (enzalutamide) is developed and commercialized in the U.S. in collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales. Pfizer receives tiered royalties as a percentage of international Xtandi net sales.
2. Bavencio® (avelumab) is co-developed and co-commercialized in collaboration with Merck KGaA, Darmstadt, Germany.
3. Pfizer has exclusive rights to Braftovi® (encorafenib) and Mektovi® (binimetinib) in the U.S. and Canada. Pfizer has granted Ono Pharmaceutical Co. Ltd. exclusive rights to commercialize the products in Japan and South Korea, Medison in Israel, and Pierre Fabre in all other countries.

4

IBRANCE (palbociclib)

First-in-Class, #1 Prescribed

CDK4/6 Inhibitor

Tami, living with metastatic Breast Cancer

5

Maintaining Ibrance Leadership

• Nearly 315,000 patients treated with Ibrance to date globally
• Use of CDK inhibitors for new metastatic breast cancer patients continues to grow
• Ibrance share of first-line CDK patients remains stable: approx. 7 out of 8 are on Ibrance
• Recent real-world data analysis(1) of Ibrance, in combination with letrozole, showed a statistically significant overall survival benefit in ER+/HER2- metastatic breast cancer when compared to letrozole alone (Hazard Ratio=0.58)

1. Presented at the 2019 San Antonio Breast Cancer Symposium (SABCS), December 10-14, 2019 (Poster P1-19-02).

Estimated U.S. first-line share of
ER+/HER2- metastatic breast cancer
70%			66%
60%			58%
50%
40%
30%			20%
20%
10%			5%
0%
Dec-16Feb-17Apr-17Jun-17Aug-17	Oct-17Dec-17Feb-18Apr-18Jun-18Aug-18	Oct-18Dec-18Feb-19Apr-19Jun-19	Aug-19Oct-19Dec-19Feb-20Apr-20
Ibrance	CDK Class	AI Mono	Chemo

Source: IQVIA PLD claims: Total patient share R3M (Dec 16 - May 2020); data has been normalized for lower coverage and may be subject to restatement, particularly in recent months

6

Up to 14 Potential Approvals by 2025 Across Targeted Therapies(1) and Immunotherapies(2)

Late-Stage

Development

		Targeted Therapies(1)				Immunotherapies(2)
Ibrance		Braftovi	Xtandi		Lorbrena		Sasanlimab + BCG		Bavencio
	BRAF+ first-line (1L)		Non-metastatic castration
HR+ / HER2-				ALK+ 1L metastatic		Non-Muscle Invasive
	metastatic colorectal		sensitive prostate cancer				1L metastatic NSCLC
early breast cancer				NSCLC		Bladder Cancer (NMIBC)
	cancer (CRC)		(nmCSPC)
Ibrance		Braftovi / Mektovi		Xtandi + Talzenna		Daurismo
		Metastatic castration-
HR+ / HER2+		BRAF+ 1L
		resistant prostate		Acute Myeloid Leukemia
metastatic breast cancer		metastatic melanoma
		cancer (All/DRR)
		Braftovi / Mektovi
		BRAF+ metastatic non-
		small cell lung cancer
		(NSCLC)

Cyclin-Dependent

Kinase (CDK) 2/4/6

Early

Development CDK4

Selected Pre-POC

Programs

CDK2

Protein arginine		HER2		HER2-Exon 20/
methyltransferase 5		Antibody Drug
		wt amp
(PRMT5)		Conjugate (ADC)
Eukaryotic translation				cMET-Exon 14/
initiation factor 4E		SHP2
		wt amp
(elF4E)
Lysine		Brain-Penetrant
acetyltransferase 6			EZH2
	BRAF
(KAT6)

B-cell maturation antigen (BCMA) CD3 bi-specific

AVB8

GUYC2C

CD3 bi-specific

TGFβR1

Vaccine-Based

Immunotherapy Regimen

(VBIR2) Cancer vaccine

AXL/MERTK

HR represents hormone receptor. HER2 represents human epidermal growth factor receptor 2.

1. Targeted Therapies include agents that directly target cancer cells
2. Immunotherapies include agents that engage the immune response to cancer cells

= Indicates potential approval by 2025

7

Up to 14 Potential Approvals by 2025 Across Targeted Therapies and Immunotherapies

Late-Stage

Development

		Targeted Therapies				Immunotherapies
Ibrance		Braftovi	Xtandi		Lorbrena		Sasanlimab + BCG		Bavencio
	BRAF+ first-line (1L)		Non-metastatic castration
HR+ / HER2-				ALK+ 1L metastatic		Non-Muscle Invasive
	metastatic colorectal		sensitive prostate cancer				1L metastatic NSCLC
early breast cancer				NSCLC		Bladder Cancer (NMIBC)
	cancer (CRC)		(nmCSPC)
Ibrance		Braftovi / Mektovi		Xtandi + Talzenna		Daurismo
		Metastatic castration-
HR+ / HER2+		BRAF+ 1L
		resistant prostate		Acute Myeloid Leukemia
metastatic breast cancer		metastatic melanoma
		cancer (All/DRR)
		Braftovi / Mektovi
		BRAF+ metastatic non-
		small cell lung cancer
		(NSCLC)

Early

Development

Selected Pre-POC

Programs

Cyclin-Dependent		Protein arginine		HER2		HER2-Exon 20/
	methyltransferase 5		Antibody Drug
Kinase (CDK) 2/4/6				wt amp
	(PRMT5)		Conjugate (ADC)
		Eukaryotic translation				cMET-Exon 14/
CDK4		initiation factor 4E		SHP2
			wt amp
		(elF4E)
		Lysine		Brain-Penetrant
CDK2		acetyltransferase 6			EZH2
		BRAF
		(KAT6)

B-cell maturation antigen (BCMA) CD3 bi-specific

AVB8

GUYC2C

CD3 bi-specific

TGFβR1

Vaccine-Based

Immunotherapy Regimen

(VBIR2) Cancer vaccine

AXL/MERTK

= Indicates potential approval by 2025 = Programs to be discussed today

8

LORBRENA/LORVIQUA (lorlatinib)

Continuing to Advance NSCLC

Treatment with a Third-Generation

ALK Inhibitor

Gina, living with

ALK-positive

Lung Cancer

9

In 2020, ~13,500 New Cases of ALK+ NSCLC Will Be Diagnosed in the G7(1),(2)

Lorlatinib Patient in CROWN Trial

Baseline	Complete Response
24 Months (Ongoing)

• Lorlatinib has increased potency compared to most ALK inhibitors, is active against the most common resistance mutations and crosses the blood-brain barrier
• Up to 40% of ALK+ NSCLC patients present with brain metastases(3)
• Lorbrena's median duration of response as a second- or third-line ALK inhibitor is 12.5 months(4)

1. Decision Resources Group. Non-Small-Cell Lung Cancer Epidemiology, 2019 [Accessed 14th August 2020]. G7 represents U.S. EU5 (Germany, United Kingdom, Italy, France and Spain) and Japan.
2. Garber K. J Natl Cancer Inst. 2010;102:672-675.
3. Peters S. N Engl J Med 2017;377:829-38
4. FDA label for lorlatinib (https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf), Section 6.1 Clinical Trials Experience.

10

BRAFTOVI & MEKTOVI (encorafinib & binimetinib)

Expanding Our Presence in BRAF-

Driven Colorectal Cancer and Melanoma

Scott, living with metastatic colorectal cancer

11

Poor Prognosis for BRAF-Mutated Metastatic Colorectal Cancer (CRC)

• CRC is the 4th leading cause of cancer-related death(1)
• In 2020, ~500,000 new CRC cases are expected to be diagnosed in the G7(2)

Disease	CRC	BRAF Mutated	Estimated 5
Diagnosed	Year Survival
Stage	Patients in G7(2)
Patients in G7(2)	(for BRAF, US)
Localized	~115,000	~8,000	80-90%
Stage 1
Regional
~275,000	~19,000	60-70%
Stage 2
Distant
~110,000	~8,000	~4%
Stage 3
Source: Decision Resource Group, Kantar Health

NOTE: Pfizer has exclusive rights to Braftovi® (encorafenib) and Mektovi® (binimetinib) in the U.S. and Canada. Pfizer has granted Ono Pharmaceutical Co. Ltd. exclusive rights to commercialize the products in Japan and South Korea, Medison in Israel, and Pierre Fabre in all other countries. Pfizer receives royalties on sales of Braftovi and Mektovi outside the U.S.

1. Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer (2019):144:2992-3000
2. G7 represents U.S., EU5 (Germany, United Kingdom, Italy, France and Spain), and Japan.

12

ANCHOR: Encouraging Activity in First-Line Metastatic Colorectal Cancer (CRC)

Phase 2 single-arm study of encorafenib, binimetinib plus

cetuximab in previously untreated BRAFV600E-mutant metastatic CRC

Best change from baseline (%)

20

10

0 -10-20-30-40-50-60-70-80-90-100

Best percentage change in tumor measurement for stage 1 of study

Investigator's assessment, patients evaluable for efficacy

* * *

• 3 patients with best percent change from baseline = 0%; Confirmed best overall response = stable disease ¤ Complete Response on target lesion but non-target lesion still present

# Complete Response was not confirmed at the subsequent tumor evaluation

¤ #

Objective Response Rate:

50.0%

Disease Control Rate:

85.0%

	Partial Response (n=20)		Stable Disease (n=14)		Progressive Disease (n=3)		Not Evaluable (n=1)

Data presented at European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 (Virtual), July 2020.

13

Anticipate Up to $2 Billion of Annual Revenue Contributions Across the BRAF/MEK portfolio in 2027(1)

CRC

Lung Melanoma

	2017	2018	2019	2020	2021	2022	2023	2024	2025
2L/3L Metastatic			Phase 3: BEACON
15K patients†
1L Metastatic					Phase 2: ANCHOR	Phase 3: BREAKWATER
17K patients†
1L Metastatic (MSI-High)								Phase 2
3K patients†
1L/2L Metastatic			Phase 3:
17K patients†			COLUMBUS
1L Metastatic with Brain						Phase 2: POLARIS
Metastases 9K patients†
1L Metastatic
(+pembrolizumab)							Phase 3: STARBOARD
10K patients†
1L Metastatic (PD-1								Phase 2
Progressor) 2K patients†
Metastatic NSCLC						Phase 2: PHAROS
16K patients†
Positive top-line report			Interim	Regulatory approval	Potential regulatory approval	Potential label enhancement in tumor
		analysis	for new tumor type		type with previous approval

1. Includes non-risk-adjusted revenue contributions from all programs/patient populations referenced above. Assumes constant foreign exchange rates.

† Estimates for appropriate patients within each target indication in the G7 (US, EU5 [Germany, United Kingdom, Italy, France and Spain] and Japan) in 2020 based on Kantar.

NOTE: All timings are approximate and subject to change.

14

Genitourinary Cancers

Expanding Our Franchise in Renal,

Bladder and Prostate Cancers:

Sutent, Inlyta, Xtandi, Bavencio,

Talzenna and sasanlimab

Chas, living with

Prostate Cancer

15

Prostate and Bladder Cancers Are the First and Fourth Most Common Cancers in Men, Respectively(1)

Prostate Cancer

• Globally, ~1.4 million new cases are expected to be diagnosed in 2020(1)
• In 2020, ~33,000 men expected to die in the U.S. from prostate cancer(2)
• ~25% of advanced prostate cancer harbor mutations in DNA Damage Response (DDR) genes(3),(4)

Bladder Cancer

• In G7, ~182,000 new patients expected to be diagnosed with non-muscle invasive bladder cancer (NMIBC) in
  2020(5),(6)
• 50-70%of patients recur or progress to muscle invasive or metastatic disease after initial treatment​ for their bladder cancer(7)

(1)World Cancer Research Fund, Accessed August 2020. (2)American Cancer Society 2019. (3) Chung JH, Dewal N, et al. JCO Precis Oncol. 2019. (4) Armenia J, Wankowicz SAM, et al.Nat Genet. 2018 . (5)G7 represents U.S., EU5 (Germany, United Kingdom, Italy, France and Spain), and Japan.

(6) Kantar Health. (7)Sylvester, van der Meijden, et al. European Association of Urology 2006

16

TALAPRO 1: Talazoparib Demonstrated Activity in Metastatic Castration-Resistant Prostate Cancer (mCRPC) with DNA Damage Response (DDR) Mutations at an Interim Analysis

A Phase 2 open-label study to assess efficacy and safety of talazoparib in men with mCRPC with a DDR alteration who have previously received taxane-based chemotherapy and progressed on at least one novel hormonal agent

of	40
baselinefromin sum lesionstargetfor (%)	20
0
	-20
Bestchange diameters	-40
-60

-80-100

Presented at ASCO 2020.

DDR Alteration

BRCA2 (n=32)		BRCA1 (n=4)		ATM (n=14)		PALB2 (n=2)		Other (n=10)

Objective response rate for tumors with BRCA 1 or 2 mutations was 41.5%

17

Developing Sasanlimab as Potential New Sub-CutaneousPD-1 Backbone

Phase 1, open-label,multi-center, dose escalation, expansion, and safety study of sasanlimab in previously treated adult patients with metastatic urothelial carcinoma

Response)	80
60
(Best	40
20
Baseline	0	PD SD SD PD
-20
from
-40
Change
-80
	-60
%	-100
	Partial Response (n=8)	Stable Disease (n=12)	Progressive Disease (n=15)

Objective response observed in 21.1% of patients;

Duration of response not yet mature with many responses ongoing

Presented at ESMO 2019.

Sasanlimab is under investigation and is not yet approved for NMIBC or in any other indication.

Phase 3 CREST Study: Sasanlimab in combination with BCG vs. BCG alone in participants with first-linehigh-risk non- muscle invasive bladder cancer

				Sasanlimab + BCG
				Induction &
				Maintenance
N=999			Sasanlimab + BCG
1:1:1
			Induction Only
Randomization
				Bacillus Calmette-
				Guerin (BCG) Induction
				& Maintenance

First patient dosed in January 2020; Expected completion date in 2024

18

Anticipate Up to $5 Billion of Annual Revenue Contributions Across the Bladder and Prostate Portfolio in 2027(1)

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Bladder

1L UC

Phase 3: JAVELIN Bladder 100

(Maintenance)

(Bavencio + BSC vs. BSC alone)

~57.5K patients†

BCG Naïve NMIBC

Phase 3: CREST

~295K patients†

(Sasanlimab + BCG vs. BCG alone)

Late

Metastatic 1L

Phase 3: TALAPRO 2

CRPC

Early-----------------------------

~130K patients†

(Talzenna + Xtandi vs. Xtandi alone)

Prostate

Non-metastatic

Phase 3: PROSPER

CRPC

(Xtandi vs. placebo)

~54K patients†

Metastatic CSPC

Phase 3: ARCHES

~90K patients†

(Xtandi + ADT vs. ADT + placebo)

Non-metastatic

Phase 3: EMBARK

CSPC

(Xtandi + leuprolide vs placebo + leuprolide vs Xtandi)

~32K patients†

Positive top-line report	Interim	Regulatory approval	Potential regulatory approval	Potential label enhancement in tumor
analysis	type with previous approval

1. Includes non-risk-adjusted revenue contributions from all programs/patient populations referenced above as well as for Xtandi monotherapy in metastatic CRPC. Assumes constant foreign exchange rates.
   † Estimates for appropriate patients within each target indication in the G7 (US, EU5 [Germany, United Kingdom, Italy, France, and Spain] and Japan) at peak year based on Kantar Health.

NOTE: All timings are approximate and subject to change.

19

Advancing Therapies to Earlier Lines with Larger Populations and Longer Treatment Durations

Late-Stage

Development

		Targeted Therapies				Immunotherapies
Ibrance		Braftovi	Xtandi		Lorbrena		Sasanlimab + BCG		Bavencio
	BRAF+ first-line (1L)		Non-metastatic castration-
HR+ / HER2-				ALK+ 1L metastatic		Non-Muscle Invasive
	metastatic colorectal		sensitive prostate cancer				1L metastatic NSCLC
early breast cancer				NSCLC		Bladder Cancer (NMIBC)
	cancer (CRC)		(nmCSPC)
Ibrance		Braftovi / Mektovi		Xtandi + Talzenna		Daurismo
		Metastatic castration-
HR+ / HER2+		BRAF+ 1L
		resistant prostate		Acute Myeloid Leukemia
metastatic breast cancer		metastatic melanoma
		cancer (All/DRR)
		Braftovi / Mektovi
		BRAF+ metastatic non-
		small cell lung cancer
		(NSCLC)

Early

Development

Selected Pre-POC

Programs

Cyclin-Dependent		Protein arginine	HER2		HER2-Exon 20/
	methyltransferase 5	Antibody Drug
Kinase (CDK) 2/4/6			wt amp
	(PRMT5)	Conjugate (ADC)
		Eukaryotic translation				cMET-Exon 14/
CDK4		initiation factor 4E		SHP2
			wt amp
		(elF4E)
		Lysine		Brain-Penetrant
CDK2		acetyltransferase 6			EZH2
		BRAF
		(KAT6)

B-cell maturation antigen (BCMA) CD3 bi-specific

AVB8

GUYC2C

CD3 bi-specific

TGFbR1

Vaccine-Based

Immunotherapy

Regimen (VBIR2)

Cancer vaccine

AXL/MERTK

20

Anticipate Up to $6 Billion of Incremental Annual Revenue Contributions in 2027 from Programs Currently in Late-Stage Development(1)

Late-Stage

Development

		Targeted Therapies				Immunotherapies
Ibrance		Braftovi	Xtandi		Lorbrena		Sasanlimab + BCG		Bavencio
	BRAF+ first-line (1L)		Non-metastatic castration-
HR+ / HER2-				ALK+ 1L metastatic		Non-Muscle Invasive
	metastatic colorectal		sensitive prostate cancer				1L metastatic NSCLC
early breast cancer				NSCLC		Bladder Cancer (NMIBC)
	cancer (CRC)		(nmCSPC)
Ibrance		Braftovi / Mektovi		Xtandi + Talzenna		Daurismo
		Metastatic castration-
HR+ / HER2+		BRAF+ 1L
		resistant prostate		Acute Myeloid Leukemia
metastatic breast cancer		metastatic melanoma
		cancer (All/DRR)
		Braftovi / Mektovi
		BRAF+ metastatic non-
		small cell lung cancer
		(NSCLC)

Early

Development

Selected Pre-POC

Programs

Cyclin-Dependent		Protein arginine	HER2		HER2-Exon 20/
	methyltransferase 5	Antibody Drug
Kinase (CDK) 2/4/6			wt amp
	(PRMT5)	Conjugate (ADC)
		Eukaryotic translation				cMET-Exon 14/
CDK4		initiation factor 4E		SHP2
			wt amp
		(elF4E)
		Lysine		Brain-Penetrant
CDK2		acetyltransferase 6			EZH2
		BRAF
		(KAT6)

B-cell maturation antigen (BCMA) CD3 bi-specific

AVB8

GUYC2C

CD3 bi-specific

TGFbR1

Vaccine-Based

Immunotherapy

Regimen (VBIR2)

Cancer vaccine

AXL/MERTK

(1) Includes non-risk-adjusted revenue contributions from all Late-Stage Development programs referenced above as well as the BCMA program currently in early development. Assumes constant foreign exchange rates

21

Early Clinical Pipeline Poised to Potentially Deliver Up to 10 New Molecular Entity Approvals by 2026

Late-Stage

Development

		Targeted Therapies					Immunotherapies
Ibrance		Braftovi	Xtandi		Lorbrena	Sasanlimab + BCG		Bavencio
	BRAF+ first-line (1L)		Non-metastatic castration-				Non-Muscle Invasive
HR+ / HER2-				ALK+ 1L metastatic
	metastatic colorectal		sensitive prostate cancer				Bladder Cancer		1L metastatic NSCLC
early breast cancer				NSCLC
	cancer (CRC)		(nmCSPC)				(NMIBC)
Ibrance		Braftovi / Mektovi		Xtandi + Talzenna		Daurismo
		Metastatic castration-
HR+ / HER2+		BRAF+ 1L
		resistant prostate		Acute Myeloid Leukemia
metastatic breast cancer		metastatic melanoma
		cancer (All/DRR)

Braftovi / Mektovi

BRAF+ metastatic non- small cell lung cancer (NSCLC)

Early

Development

Selected Pre-POC

Programs

Cyclin-Dependent		Protein arginine		HER2		HER2-Exon 20/
	methyltransferase 5		Antibody Drug
Kinase (CDK) 2/4/6				wt amp
	(PRMT5)		Conjugate (ADC)
		Eukaryotic translation				cMET-Exon 14/
CDK4		initiation factor 4E		SHP2
			wt amp
		(elF4E)
		Lysine		Brain-Penetrant
CDK2		acetyltransferase 6			EZH2
		BRAF
		(KAT6)

B-cell maturation antigen (BCMA) CD3 bi-specific

AVB8

GUYC2C

CD3 bi-specific

TGFbR1

Vaccine-Based

Immunotherapy

Regimen (VBIR2)

Cancer vaccine

AXL/MERTK

22

Investigational CDK Inhibitors & Other Novel Mechanisms

Building an R&D Pipeline of Potentially

First-in-Class,Next-Generation

Medicines for Breast Cancer and Beyond

Kaye, living with metastatic breast cancer

23

Targeting the Cancer Cell Cycle with a Strong Portfolio of Investigational Next-Generation CDK Inhibitors

CDK2/4/6

Cyclin D	Cyclin D
CDK6
CDK4
Cyclin E
	CDK2
	Cyclin A
	CDK2

Addressing Ibrance

refractory/relapse disease

Expansion opportunities in triple negative breast and ovarian cancers

Proof of mechanism expected in 2021

CDK4-selective	CDK2-selective
Cyclin D	Cyclin E
CDK4	CDK2
	Cyclin A
	CDK2

Potential improvement in efficacy & safety		Precision medicine opportunity
over Ibrance in HR+ breast cancer		in multiple tumor types
Combination opportunities in lung, colorectal		Combination potential with SOC,
and prostate cancer		targeted therapies and immuno-oncology
First-in-patient expected in 2020		First-in-patient expected in 2020

24

Next-GenerationAnti-HER2 Antibody Drug Conjugate (ADC) with Potential for Significant Differentiation

PF-06804103 Phase 1 Dose Escalation

	60			Gastric or esophageal cancer
Response)	40			Breast cancer
20
	SD SD SD NE SD SD SD SD SD SD SD SD NE PR SD PR SD PR PR PR PR SD CR PR PR PR CR PR
(Best	0
PD PD PD
Baseline	-20
-40
from
Change	-60
-80
%
	-100	3.0 mg/kg (N=11)	4.0 mg/kg (N=14)	5.0 mg/kg (N=6)
		TDM1-refractory (N=6)	TDM1-refractory (N=5)	TDM1-refractory (N=5)

Objective response rate in response-evaluable patients at the recommended Phase 2 dose of 4.0 mg/kg was 71%*

* Includes confirmed and unconfirmed responses.

• Highly stable site-specific drug conjugation
• Potent, cell-permeable auristatin payload enables bystander efficacy
• Robust Phase 1 responses in TDM1-refractory HER2+ cancers
• No interstitial lung disease reported

25

Differentiated Anti-HER2 ADC with Potential Beyond HER2+ Breast Cancer

Strong Tumor Regression in HER2-low NSCLC PDX Models

			PDX NSX 26116 HER2 Low
	1000
3)	750
(mm
vol	500						Vehicle
Tumor
250						T-DM1 6 mg/kg
							PF-06804103 3 mg/kg
	0
	0	10	20	30	40	50	60	70

Days post-randomization

PDX NSX 26110 HER2 Low

3)	2000
(mm	1500																									Vehicle
vol	1000
																								T-DM1 6 mg/kg
Tumor
	500																									PF-06804103 3 mg/kg

0	10	20	30	40	50	60
0

Days post-randomization

Potent tumor regression in pre-clinical tumor models that are largely refractory to T-DM1;

Expansion in HER2-low ER+ breast cancer with Ibrance and HER2-low NSCLC

26

BCMA Bispecific Phase 1 Data Suggest a Potentially Transformative Therapy for

Multiple Myeloma (MM) (160K New Patients Annually(1))

	BOR	215 µg/kg	360 µg/kg	600 µg/kg	1000 µg/kg	Total
	Responders / # Evaluable	3/4	3/4	4/6	5*/6	15*/20
	ORR (Partial Response or better)	75%	75%	67%	83%*	75%*
	Stringent Complete Response (sCR)	50%	25%	33%	17%*	30%*
	/ Complete Response (CR) Rate
	Cytokine Release Syndrome (CRS)	Grade 1-2	Grade 1-2	Grade 1-2	Grade 1-2

• Optimized for affinity for BCMA and CD3; more potent tumor cell toxicity
• >50 patients with late-line multiple myeloma enrolled, dose escalation completed; registrational study start expected by end of 2020
• Subcutaneous once-weekly dosing shows reduced CRS severity (grade 1 & 2 only) compared to intravenous administration; currently evaluating dosing once every 2 weeks; convenient for patients & physicians
• ORR* of 75%, with 30%* CR/sCR rate in the 4 consecutive subcutaneous dose levels so far (n=20)
• Responses observed in subjects following multiple lines of prior therapy, including BCMA-ADC and BCMA-CAR-T

* Some responses to be verified.

(1) Bray, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer. September 2018. URL: https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21492

27

World Class Drug Discovery at Pfizer-Boulder

Advancing Potential First-in-Class

Targeted Agents, Creating

Differentiated Dendritic Cell-Targeted

I/O Therapies, with Track Record in

Drugging RAS/RAF/MEK Signaling

Gary, living with metastatic melanoma with a BRAF mutation

28

Potentially First-in-Class Selective AXL/MER Tyrosine Kinase

Inhibitor in Multiple Tumor Areas

AXL & MER mediate immune suppression within	Pre-clinical data shows durable anti-tumor immunity as a
the tumor microenvironment	single agent & in combination

	1500	dosing period	vehicle				 retumor-challenge
)
3					0/8 cures
(mm
volume	1000				0/8 cures
					α -PD-1	ARRY-067
					60%TGI
					60%TGI
tumor						2/8 cures				tumor-naivere-challenge
500
											7/7 outgrowth
+ARRY-067						ARRY-067 + α -PD-1				ARRY-067 cures: 0/2 outgrowth
							100%TGI
	00						8/8 cures					ARRY-067 + α -PD-1 cures: 0/7 outgrowth
	10	20	30	40	50	60	70	80	90	100	110	120	130	140	150
	

implant MC-38 cells

Initial opportunity in lung & gastric cancers, with additional potential utility in renal cell carcinoma & melanoma​

Dendritic Cell

First patient dosed in September 2020; proof of mechanism expected in Q4 2020

29

Potentially First-in-ClassBrain-Penetrant BRAF Inhibitor

Brain-penetrant BRAF opportunity in melanoma

• 20% of BRAF melanoma patients present with brain metastases at first diagnosis1,2
• Greater than 50% progression to CNS metastasis over the course of the disease2
• Efficacy of all current BRAF inhibitors is limited by poor brain penetrance

First-in-patient expected in September 2020

A375V600E melanoma intracranial implant

	1E+2
	1E+1				Vehicle
Flux (Photons/sec) % of Day 2	1E+0
							Binimetinib + Encorafenib
1E-1
	1E-2						Binimetinib + ARRY-461
	1E-3
	0	5	10	15	20	25	30	35	40	45	50

Time (Days)

(1) Ramanujam, S. Chin Clin Oncol 2015; 4(2): 25. (2) Han, C.H.; Brastianos, P.K. Frontiers in Oncology 2017; 7: Article 230.

30

Additional Targeted Next-Generation Programs Expected to Enter Clinic in 2021

	HER2-Exon 20/wt amp Opportunity		cMET-Exon 14/wt amp Opportunity
	• 3.5% of all cancers harbor activating		• cMET exon 14 alterations in NSCLC
	mutations of HER2(1)		present with 3-4%frequency(4-6)
	• Exon 20 aberrations present in 1.5% of		• cMET amplification recognized
	NSCLC(2),(3)		driver and resistance mechanism
	• Amplified wild-type HER2 is a clinically		• Altered cMET is a clinically validated
	validated target		target
	• Current inhibitors are not selective for		• Current inhibitors do not address brain
	HER2 nor fully brain penetrant		metastases or target resistance mutations
X-ray crystal structure
First-in-patient expected in 2021		First-in-patient expected in 2021
HER2insYVMA + AR504601

1. Pahuja et al., Cancer Cell, 2018;34-792-806(2) Robichaux et al., Cancer Cell, 2019;36:444-457.(3) Sonobe et al., J Molecular Diagnostics, 2006;8:351-356.

1. Collisson et al., Nature 2014;511:543-550(5) Frampton et al., Cancer Discovery 2015;5:850-860(6) Schrock et al., J Thoracic Onc. 2016;11:1493-1502

31

Summary of Key Assumptions That Support Significant Commercial Opportunities for Programs Currently in Late-Stage Development

Investigational	Potential Indication	G7 Annual Diagnoses	Projected Share of	Projected Duration of
Therapy	(Treatment Eligible)	Annual Diagnoses	Therapy
Lorbrena	First-line metastatic	12K-15K	20%+	20-30 months
(lorlatinib)	ALK+ NSCLC
Braftovi	First-line BRAF-
mutated metastatic	4K-6K(1)	60%-70%	6-12 months
(encorafenib)
colorectal cancer
Talzenna	First-line metastatic
castration-resistant	125K-135K	10%-20%	12-24 months
(talazoparib)
prostate cancer
	First-linehigh-risk
Sasanlimab	non-muscle invasive	95K-110K	15%-25%	8-16 months
	bladder cancer

1. Braftovi annual diagnoses reflect U.S. only, not G7. Pfizer has exclusive rights to Braftovi® (encorafenib) and Mektovi® (binimetinib) in the U.S. and Canada. Pfizer has granted Ono Pharmaceutical Co. Ltd. exclusive rights to commercialize the products in Japan and South Korea, Medison in Israel, and Pierre Fabre in all other countries.

32

We Are Determined to Deliver for People Living with Cancer

	23		Up to		Up to
		24		14
	approved		NMEs in the clinic		potential
	cancer medicines
		expected by 2021		approvals by 2025
	& biosimilars

33

Thank you

34

Appendix

Compound	Mechanism
Number
PF-06801591	Sasanlimab Biologic
PF-06873600	CDK 2/4/6 Small Molecule
PF-07104091	CDK 2 Small Molecule
PF-07220060	CDK 4 Small Molecule
PF-07248144	KAT6 Small Molecule
PF-07292554	eIF4E Small Molecule
PF-06939999	PRMT5 Small Molecule
PF-06804103	HER2 Biologic ADC
PF-07284892	SHP2 Small Molecule
PF-06821497	EZH2 Small Molecule

	Compound	Mechanism
	Number
	PF-07284890	BRAF BP Small Molecule
	PF-04217903	cMET-Exon 14/wt amp Small Molecule
	70DCN02149	HER2-Exon 20/wt amp Small Molecule
	PF-06863135	BCMA Biologic
	PF-06940434	AVB8 Biologic
	PF-07062119	GUCY2c Biologic
	PF-06952229	TGfbR1 Small Molecule
	PF-06936308	VBIR2 Cancer Vaccine
	PF-07265807	AXL/MERTK Small Molecule

35